Patisiran, in the APOLLO trial (n= 225), significantly improved neuropathy, autonomic symptoms, and cardiacbiomarkers in a cardiac subgroup, with sustained TTR knockdown and favorabletolerability [81]. Here, TTR is linked to neuropathy.